3'-Ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction

BMC Cancer

Hiroto Fukushima¹  Tetsuya Abe¹  Kazuki Sakamoto¹  Hiroaki Tsujimoto¹  Shinji Mizuarai¹  Shinji Oie¹ 

[1] Biomarker Research, Tsukuba Research Center, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan

关键词: Resistance;    Biomarker;    Cisplatin;    Vaults;    ECyd;   

Others  :  1125246
DOI  :  10.1186/1471-2407-14-562

 received in 2014-01-31, accepted in 2014-07-17,  发布年份 2014

【 摘 要 】

Background

We previously reported that 3'-ethynylcytidine (ECyd, TAS-106), an RNA polymerases inhibitor, enhances the anti-tumor efficacy of platinum in several tumor types in both in vitro and in vivo tumor models. However, the molecular mechanisms underlying the ECyd-induced enhancement remain elusive.

Methods

Cisplatin (CDDP)-resistant head and neck cancer KB cells were established by stepwise dose escalation with CDDP. The combination effect of ECyd and CDDP were assessed using isobologram analysis. The transcriptional and post-translational statuses of several molecules were detected using real-time PCR, immunoblot analysis and immunocytochemistry. Xenograft assays were used to confirm the mechanisms underlying the ECyd induced enhancement of CDDP anti-tumor efficacy in vivo.

Results

ECyd sensitized KB to CDDP by inhibiting the drug transporter Vault complex (Vaults). First, we showed that Vaults were overexpressed in CDDP-resistant KB cells. The suppression of major vault protein (MVP) by RNA interference restored the sensitivity to CDDP. Next, we showed that ECyd significantly sensitized the resistant cells to CDDP, compared with the parental paired cell line. A molecular analysis revealed that ECyd inhibited the synthesis of vRNAs as well as the induction of MVP, both of which are critical components of Vaults as a drug transporter. Furthermore, we found that the synergistic effect of ECyd and CDDP was correlated with the MVP expression level when the effect was analyzed in additional cancer cell lines. Finally, we demonstrated that ECyd decreased the vRNAs expression level in xenograft tumor.

Conclusions

Our data indicated the ability of ECyd to cancel the resistance of cancer cells to CDDP by inhibiting the Vaults function and the decrease of Vaults expression itself, and the ability of the combination therapy with CDDP and ECyd to offer a new strategy for overcoming platinum resistance. Moreover, the study results suggest that Vaults could be a biomarker for stratifying patients who may benefit from the combination therapy with ECyd and platinum.

【 授权许可】

   
2014 Fukushima et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Matsuda A, Sasaki T: Antitumor activity of sugar-modified cytosine nucleosides. Cancer Sci 2004, 95:105-111.
• [2]Van Rompay AR, Norda A, Lindén K, Johansson M, Karlsson A: Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol 2001, 59:1181-1186.
• [3]Shimamoto Y, Fujioka A, Kazuno H, Murakami Y, Ohshimo H, Kato T, Matsuda A, Sasaki T, Fukushima M: Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine. Jpn J Cancer Res 2001, 92:343-351.
• [4]Takatori S, Kanda H, Takenaka K, Wataya Y, Matsuda A, Fukushima M, Shimamoto Y, Tanaka M, Sasaki T: Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil. Cancer Chemother Pharmacol 1999, 44:97-104.
• [5]Murata D, Endo Y, Obata T, Sakamoto K, Syouji Y, Kadohira M, Matsuda A, Sasaki T: A crucial role of uridine/cytidine kinase 2 in antitumor activity of 3'-ethynyl nucleosides. Drug Metab Dispos 2004, 32:1178-1182.
• [6]Shimamoto Y, Koizumi K, Okabe H, Kazuno H, Murakami Y, Nakagawa F, Matsuda A, Sasaki T, Fukushima M: Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2. Jpn J Cancer Res 2002, 93:825-833.
• [7]Kazuno H, Fujioka A, Fukushima M, Wataya Y, Matsuda A, Sasaki T: 1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl) cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo. Int J Oncol 2009, 34:1373-1380.
• [8]Argiris A, Karamouzis MV, Raben D, Ferris RL: Head and neck cancer. Lancet 2008, 371:1695-1709.
• [9]Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, Clarkson JE, Macluskey M, Chan KK, Conway DI: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev 2011., 13CD006386
• [10]Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584.
• [11]Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S, Kuwano M: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 1996, 56:4124-4129.
• [12]Izquierdo MA, Scheffer GL, Schroeijers AB, de Jong MC, Scheper RJ: Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP. Cytotechnology 1998, 27:137-148.
• [13]Mayer F, Honecker F, Looijenga LH, Bokemeyer C: Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann Oncol 2003, 14:825-832.
• [14]Wang W, Ke S, Chen G, Gao Q, Wu S, Wang S, Zhou J, Yang X, Lu Y, Ma D: Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines. Oncol Rep 2004, 12:1365-1370.
• [15]Oue T, Yoneda A, Uehara S, Yamanaka H, Fukuzawa M: Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies. J Pediatr Surg 2009, 44:377-380.
• [16]Silva P, West CM, Slevin N, Valentine H, Ryder WD, Hampson L, Bibi R, Sloan P, Thakker N, Homer J, Hampson I: Tumor expression of major vault protein is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007, 69:133-140.
• [17]Kedersha NL, Rome LH: Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol 1986, 103:699-709.
• [18]Vilalta A, Kickhoefer VA, Rome LH, Johnson DL: The rat vault RNA gene contains a unique RNA polymerase III promoter composed of both external and internal elements that function synergistically. J Biol Chem 1994, 269:29752-29759.
• [19]Kickhoefer VA, Siva AC, Kedersha NL, Inman EM, Ruland C, Streuli M, Rome LH: The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol 1999, 146:917-928.
• [20]Kickhoefer VA, Stephen AG, Harrington L, Robinson MO, Rome LH: Vaults and telomerase share a common subunit, TEP1. J Biol Chem 1999, 274:32712-32717.
• [21]Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, Theodorus H, Van Heijningen M, Coen K, Van K, Slovak ML, Elisabeth G, de Vries E, van der Valk P, Chris JL, Meijer M, Pinedo HM: Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993, 53:1475-1479.
• [22]Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995, 1:578-582.
• [23]Schroeijers AB, Siva AC, Scheffer GL, de Jong MC, Bolick SC, Dukers DF, Slootstra JW, Meloen RH, Wiemer E, Kickhoefer VA, Rome LH, Scheper RJ: The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines. Cancer Res 2000, 60:1104-1110.
• [24]Bouhamyia L, Chantot-Bastaraud S, Zaidi S, Roynard P, Prengel C, Bernaudin JF, Fleury-Feith J: Immunolocalization and cell expression of lung resistance-related protein (LRP) in normal and tumoral human respiratory cells. J Histochem Cytochem 2007, 55:773-782.
• [25]Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, van der Valk P, Scheper RJ: Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996, 48:877-887.
• [26]Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ, Rome LH: Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem 1998, 273:8971-8974.
• [27]Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Beliën JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJ, de Vries EG, Scheper RJ: Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995, 87:1230-1237.
• [28]Filipits M, Drach J, Pohl G, Schuster J, Stranzl T, Ackermann J, Königsberg R, Kaufmann H, Gisslinger H, Huber H, Ludwig H, Pirker R: Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res 1999, 5:2426-2430.
• [29]Ohno N, Tani A, Uozumi K, Hanada S, Furukawa T, Akiba S, Sumizawa T, Utsunomiya A, Arima T, Akiyama S: Expression of functional lung resistance–related protein predicts poor outcome in adult T-cell leukemia. Blood 2001, 98:1160-1165.
• [30]Poderycki MJ, Kickhoefer VA, Kaddis CS, Raval-Fernandes S, Johansson E, Zink JI, Loo JA, Rome LH: The vault exterior shell is a dynamic structure that allows incorporation of vault-associated proteins into its interior. Biochemistry 2006, 45:12184-12193.
• [31]Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA: Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene 2003, 22:7458-7467.
• [32]Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987, 47:936-942.
• [33]Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979, 5:85-91.
• [34]van Zon A, Mossink MH, Schoester M, Scheffer GL, Scheper RJ, Sonneveld P, Wiemer EA: Multiple human vault RNAs. Expression and association with the vault complex. J Biol Chem 2001, 276:37715-37721.
• [35]Shimamoto Y, Sumizawa T, Haraguchi M, Gotanda T, Jueng HC, Furukawa T, Sakata R, Akiyama S: Direct activation of the human major vault protein gene by DNA-damaging agents. Oncol Rep 2006, 15:645-652.
• [36]Berger W, Elbling L, Micksche M: Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 2000, 88:293-300.
• [37]Hattori H, Tanaka M, Fukushima M, Sasaki T, Matsuda A: Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. J Med Chem 1996, 39:5005-5011.
• [38]Kickhoefer VA, Searles RP, Kedersha NL, Garber ME, Johnson DL, Rome LH: Vault ribonucleoprotein particles from rat and bullfrog contain a related small RNA that is transcribed by RNA polymerase III. J Biol Chem 1993, 268:7868-7873.
• [39]Ikeda R, Iwashita K, Sumizawa T, Beppu S, Tabata S, Tajitsu Y, Shimamoto Y, Yoshida K, Furukawa T, Che XF, Yamaguchi T, Ushiyama M, Miyawaki A, Takeda Y, Yamamoto M, Zhao HY, Shibayama Y, Yamada K, Akiyama S: Hyperosmotic stress up-regulates the expression of major vault protein in SW620 human colon cancer cells. Exp Cell Res 2008, 314:3017-3026.
• [40]Naing A, Fu S, Zinner RG, Wheler JJ, Hong DS, Arakawa K, Falchook GS, Kurzrock R: Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. Invest New Drugs 2014, 32:154-159.